How much does he fact the exact same drug (Bavi) has been used in other trials (two others with Doce) with similar results help to alleviate the risk that the p ratio came in at .21? Add to that that the 1mg arm also showed activity and when combined the 1mg + 3mg were stat sig against the original control arm.
IMO if a BP is unwilling to see that the risk of the lack of stat sig in the 2nd line lung trial is mitigated by these factors they need to keep looking for another partner because they are choosing to use the risk as a negotiating tool against pphm.
News 
Market Data 
Discover 
